HUTCHMED (NASDAQ:HCM - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued to clients and investors on Friday.
Separately, HSBC lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th.
Check Out Our Latest Analysis on HCM
HUTCHMED Trading Up 0.6%
NASDAQ:HCM traded up $0.09 on Friday, reaching $15.35. 60,613 shares of the company's stock were exchanged, compared to its average volume of 100,811. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68. HUTCHMED has a 52 week low of $11.51 and a 52 week high of $21.50. The stock has a fifty day simple moving average of $14.05 and a 200-day simple moving average of $14.80.
Hedge Funds Weigh In On HUTCHMED
A number of large investors have recently modified their holdings of HCM. Blue Trust Inc. boosted its position in shares of HUTCHMED by 99.9% in the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock valued at $102,000 after acquiring an additional 3,532 shares during the period. XY Capital Ltd bought a new position in shares of HUTCHMED in the fourth quarter valued at approximately $673,000. Summit Trail Advisors LLC boosted its position in shares of HUTCHMED by 14.4% in the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock valued at $189,000 after acquiring an additional 1,647 shares during the period. ABC Arbitrage SA bought a new position in shares of HUTCHMED in the fourth quarter valued at approximately $500,000. Finally, OLD Mission Capital LLC bought a new position in shares of HUTCHMED in the fourth quarter valued at approximately $230,000. 8.82% of the stock is currently owned by institutional investors.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
